Financials
Financial year 2025
Tiline Pharma from Hove, company number BE0794425941, closed financial year 2025 with a result of € 16,560 after tax. For that financial year Tiline Pharma recorded a gross margin of € 24,266 and equity of € 48,627. Compared with financial year 2024, the result moved from € 25,277 to € 16,560. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 13, 2026.
€ 48,627
▲ 52% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 16,560
▼ 34% vs 2024
Profit after tax over the fiscal year.
€ 55,491
▲ 2% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 43,627.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 339
▼ 52% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 14,363
▼ 18% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 3,795 | € 35,415 | € 24,266 | ▼ 31% |
| Profit after taxes | € 1,790 | € 25,277 | € 16,560 | ▼ 34% |
| Equity | € 6,790 | € 32,067 | € 48,627 | ▲ 52% |
| Total debts | € 7,386 | € 22,571 | € 22,863 | ▲ 1% |
| Cash | € 14,176 | € 54,638 | € 55,491 | ▲ 2% |
| Retained profit | € 1,790 | € 27,067 | € 43,627 | ▲ 61% |
| Balance sheet total | € 14,176 | € 54,638 | € 71,491 | ▲ 31% |
Key figures of Tiline Pharma, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Tiline Pharma?
What happened at Tiline Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 16,560 (▼ 34% vs 2024). filed late Source: NBB ↗
- New establishment in Hove. KBO
- Eline Vander Borght became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 1,790 profit in 2023 to € 16,560 profit in 2025.
Paid € 17,293 in corporate taxes since 2023.
Best year ever: 2024, with € 25,277 profit.
Management
Behind Tiline Pharma is Eline Vander Borght. Eline Vander Borght is also behind APOTHEEK ELSDONK and Pharmical.
Directors
According to the 2025 annual accounts
since 2022
Establishments
Establishment units
Physical locations of this company
Azalealei 43
2540 Hove
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0794.425.941
- VAT number
- BE 0794.425.941
- Registered office
- Azalealei 43, 2540 Hove
- Names & denominations
- Tiline Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 6 December 2022
- Peppol
- Active · Active since 2 Dec 2025
- Activities · NACE
Activiteiten van hoofdkantoren
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies